A Phase 4 interventional study of Tirzepatide and Antihyperglycemic medication in Type 2 Diabetes, sponsored by Eli Lilly and Company. Active, not recruiting at 90 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 4 that started in 2022, is one of 10 in phase 4, reaches primary completion later than 3 of the 12 other live ones, and was the 22nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 794 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 37th largest by enrollment of the 232 interventional ones that give a count, is one of 11 that started in 2022, is one of 33 in phase 4, reaches primary completion later than 0 of the 20 other live ones, and was the 185th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have been on a stable treatment of metformin only at least 90 days preceding baseline
Exclusion Criteria:
Have a history of
Are at high risk for cardiovascular disease (CVD) in the investigator's opinion or have a history of any of these CV conditions prior to study entry
Have been treated with any injectable glucagon-like peptide-1 (GLP-1) receptor agonists and insulin prior to screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 104 weeks. The starting dose of tirzepatide was 2.5 mg QW, which was increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5mg to 15 mg) until 15 mg or maximum tolerated dose (MTD) was reached.
Drug: Tirzepatide
Participants received a glucose-lowering medication selected by the investigator, in accordance with local treatment guidelines and country-specific product labeling for 104 weeks.
Drug: Antihyperglycemic medication
Administered SC
Also known as: LY3298176
As prescribed
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Change From Baseline in HbA1c
Time frame: Baseline, Week 208
Change From Baseline in Weight
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Change From Baseline in Weight
Time frame: Baseline, Week 208
Change From Baseline in Waist Circumference
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 208
Change From Baseline in Fasting Serum Glucose (FSG)
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Change From Baseline in Fasting Serum Glucose
Time frame: Baseline, Week 208
Percent Change From Baseline in Total Serum Cholesterol
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Percent Change From Baseline in Total Serum Cholesterol
Time frame: Baseline, Week 208
Percent Change From Baseline in Serum Triglycerides
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Percent Change From Baseline in Serum Triglycerides
Time frame: Baseline, Week 208
Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol
Time frame: Baseline, Week 208
Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol
Values represented under Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol
Time frame: Baseline, Week 208
Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 104
Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol
Time frame: Baseline, Week 208
Percentage of Participants Achieving HbA1c <7.0%
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Week 104
Percentage of Participants Achieving HbA1c <7.0%
Time frame: Week 208
Percentage of Participants Achieving HbA1c ≤6.5%
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Week 104
Percentage of Participants Achieving HbA1c ≤6.5%
Time frame: Week 208
Percentage of Participants Achieving HbA1c <5.7%
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Week 104
Percentage of Participants Achieving HbA1c <5.7%
Time frame: Week 208
Percentage of Participants With >=5% Weight Loss From Baseline
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Baseline, Week 104
Percentage of Participants With >=5% Weight Loss From Baseline
Time frame: Baseline, Week 208
Percentage of Participants With >=10% Weight Loss From Baseline
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Baseline, Week 104
Percentage of Participants With >=10% Weight Loss From Baseline
Time frame: Baseline, Week 208
Percentage of Participants With >=15% Weight Loss From Baseline
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Baseline, Week 104
Percentage of Participants With >=15% Weight Loss From Baseline
Time frame: Baseline, Week 208
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)
A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Percentage of participants was calculated by dividing the number of participants reaching target HbA1c, weight loss, no Hypoglycemia by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
Time frame: Week 104
Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia)
Time frame: Week 208
Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)
β-cell Glucose Sensitivity assessed by Oral Glucose Tolerance Test (OGTT). LS mean was determined using ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
Time frame: Baseline, Week 104
Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT)
Time frame: Baseline, Week 208
Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation)
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment. Insulin secretion rate adjusted for basal potentiation was defined as the ISR at a fixed glucose concentration of 9.2 mmol/L, adjusted for time-dependent potentiation of insulin secretion, and is expressed in pmol/min/m².
Time frame: Baseline, Week 104
Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration
Time frame: Baseline, Week 208
Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
Time frame: Baseline, Week 104
Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS)
Time frame: Baseline, Week 208
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180])
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
Time frame: Baseline, Week 104
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total AUC[0-180])
Time frame: Baseline, Week 208
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
Time frame: Baseline, Week 104
Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180])
Time frame: Baseline, Week 208
Change From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: Physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). Items in Physical Function describe physical impacts related to general and specific physical activities. All items in physical domain are rated on a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined by MMRM model for post-baseline measures: Variable=Baseline + Geographic Region+Baseline HbA1c Group + Age + Treatment\*Time. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline)=Unstructured.
Time frame: Baseline, Week 104
Change From Baseline in the IWQOL-Lite-CT - Physical Functioning Score
Time frame: Baseline, Week 208
The current results reported are for the primary completion date (i.e., up to 104 weeks). Additional results (week 208) will be reported at the time of final results reporting.
| Milestone | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Started | 398 | 396 |
| Received at least one dose of study drug | 397 | 395 |
| Completed | 359 | 350 |
| Not completed | 39 | 46 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Assigned treatment by mistake | 6 | 3 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 9 | 12 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Protocol deviation | 1 | 2 |
| Withdrew: Withdrawal by subject | 12 | 19 |
| Withdrew: Other | 5 | 6 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percentage of HbA1c | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -2.24 ± 0.053 | -1.45 ± 0.052 |
Results for this outcome have not been posted.
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| Kilogram (kg) | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Weight | -15.8 ± 0.518 | -6.48 ± 0.513 |
Results for this outcome have not been posted.
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| centimeter (cm) | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Waist Circumference | -13.30 ± 0.467 | -6.08 ± 0.463 |
Results for this outcome have not been posted.
Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| milligram per deciliter (mg/dL) | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -60.1 ± 1.455 | -42.7 ± 1.438 |
Results for this outcome have not been posted.
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: Variable = Baseline + Geographic Region + Age + Treatment\*Time. Variance-covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percent Change From Baseline in Total Serum Cholesterol | -2.60 ± 1.072 | -2.76 ± 1.073 |
Results for this outcome have not been posted.
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percent Change From Baseline in Serum Triglycerides | -29.9 ± 1.577 | -13.61 ± 1.949 |
Results for this outcome have not been posted.
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percent Change From Baseline in Serum Low-density Lipoprotein (LDL) Cholesterol | 0.55 ± 1.919 | -3.19 ± 1.853 |
Results for this outcome have not been posted.
Values represented under Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c Group + Age + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percent Change From Baseline in Serum Very-low-density Lipoprotein (VLDL) Cholesterol | -29.0 ± 1.579 | -12.84 ± 1.945 |
Results for this outcome have not been posted.
Values represented under "Geometric Mean" are model-based estimates (MBE). MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Geographic Region + Baseline HbA1c. Variance-Covariance structure (Change from Baseline) = Unstructured.
| Percent change | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percent Change From Baseline in Serum High-density Lipoprotein (HDL) Cholesterol | 13.13 ± 1.048 | 5.01 ± 0.973 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants Achieving HbA1c <7.0% | 95.06 | 77.94 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants Achieving HbA1c ≤6.5% | 91.0 | 65.50 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participant | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants Achieving HbA1c <5.7% | 68.84 | 26.65 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants With >=5% Weight Loss From Baseline | 84.98 | 52.90 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants With >=10% Weight Loss From Baseline | 67.62 | 28.06 |
Results for this outcome have not been posted.
Percentage of participants was calculated by dividing the number of participants reaching target weight loss by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants With >=15% Weight Loss From Baseline | 49.23 | 12.80 |
Results for this outcome have not been posted.
A composite endpoint is defined as HbA1c ≤ 6.5%, weight loss ≥ 10%, and no hypoglycemia, defined as blood glucose (BG) \<3.0 millimole/liter (mmol/L) and/or severe hypoglycemia. Percentage of participants was calculated by dividing the number of participants reaching target HbA1c, weight loss, no Hypoglycemia by the total number of participants analyzed, multiplied by 100. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable. Missing data were imputed 100 times. Statistical inference for endpoint used Rubin's Rule to combine analyses of imputed datasets.
| percentage of participants | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Percentage of Participants Who Achieved Composite Endpoint (HbA1c <=6.5%, Weight Loss >=10%, and No Hypoglycemia) | 61.80 | 22.69 |
Results for this outcome have not been posted.
β-cell Glucose Sensitivity assessed by Oral Glucose Tolerance Test (OGTT). LS mean was determined using ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
| pmol/min/m^2/mM | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline Beta (β) Cell Glucose Sensitivity Using Mari's Model During Oral Glucose Tolerance Test (OGTT) | 55.10 ± 2.738 | 36.00 ± 2.725 |
Results for this outcome have not been posted.
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment. Insulin secretion rate adjusted for basal potentiation was defined as the ISR at a fixed glucose concentration of 9.2 mmol/L, adjusted for time-dependent potentiation of insulin secretion, and is expressed in pmol/min/m².
| pmol/min/m^2 | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Insulin Secretion Rate at a Fixed Glucose Concentration (Adjusted for Basal Potentiation) | 168.72 ± 13.130 | 131.24 ± 13.069 |
Results for this outcome have not been posted.
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
| mL/min/m^2 | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Oral Glucose Insulin Sensitivity (OGIS) | 95.95 ± 5.109 | 58.98 ± 5.092 |
Results for this outcome have not been posted.
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
| min*mmol/L | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Total Area Under the Curve [AUC0-180]) | -1260.39 ± 28.841 | -897.05 ± 28.930 |
Results for this outcome have not been posted.
LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Geographic Region + Baseline HbA1c Group + Age + Treatment.
| min*mmol/L | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in Post-challenge Glucose During Oral Glucose Tolerance Test (OGTT) (Incremental AUC[0-180]) | -611.83 ± 21.623 | -387.12 ± 21.657 |
Results for this outcome have not been posted.
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life: Physical (7 items, where 5 of the items comprise the physical functioning sub-domain) and psychosocial (13 items). Items in Physical Function describe physical impacts related to general and specific physical activities. All items in physical domain are rated on a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life. LS mean was determined by MMRM model for post-baseline measures: Variable=Baseline + Geographic Region+Baseline HbA1c Group + Age + Treatment\*Time. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline)=Unstructured.
| score on a scale | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| Change From Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Functioning Score | 13.96 ± 0.951 | 9.33 ± 0.961 |
Results for this outcome have not been posted.
Collected over Baseline up to Week 104. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide | 2/397 (0.5%) | 22/397 (5.5%) | 223/397 (56.2%) |
| Intensified Conventional Care (ICC) | 2/395 (0.5%) | 27/395 (6.8%) | 165/395 (41.8%) |
| Event | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/397 | 2/395 |
| CholecystitisHepatobiliary disorders | 2/397 | 0/395 |
| Cholecystitis acuteHepatobiliary disorders | 2/397 | 1/395 |
| Aortic aneurysmVascular disorders | 2/397 | 0/395 |
| Intermenstrual bleedingReproductive system and breast disorders | 0/181 | 1/210 |
| Uterine polypReproductive system and breast disorders | 0/181 | 1/210 |
| Seminal vesicular cystReproductive system and breast disorders | 1/216 | 0/185 |
| BradycardiaCardiac disorders | 0/397 | 1/395 |
| Myocardial infarctionCardiac disorders | 0/397 | 1/395 |
| Ventricular fibrillationCardiac disorders | 0/397 | 1/395 |
| Event | Tirzepatide | Intensified Conventional Care (ICC) |
|---|---|---|
| NauseaGastrointestinal disorders | 90/397 | 69/395 |
| DiarrhoeaGastrointestinal disorders | 87/397 | 53/395 |
| DyspepsiaGastrointestinal disorders | 68/397 | 25/395 |
| ConstipationGastrointestinal disorders | 57/397 | 46/395 |
| VomitingGastrointestinal disorders | 55/397 | 41/395 |
| EructationGastrointestinal disorders | 27/397 | 6/395 |
| InfluenzaInfections and infestations | 18/397 | 23/395 |
| Decreased appetiteMetabolism and nutrition disorders | 22/397 | 14/395 |
| HeadacheNervous system disorders | 22/397 | 12/395 |
| NasopharyngitisInfections and infestations | 10/397 | 21/395 |
All randomized participants.
| Age, Continuous(years) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| Mean | 53.7 ± 10.8 | 53.2 ± 9.7 | 53.5 ± 10.3 |
| Sex: Female, Male(Participants) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| Female | 181 | 211 | 392 |
| Male | 217 | 185 | 402 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| Hispanic or Latino | 42 | 37 | 79 |
| Not Hispanic or Latino | 45 | 48 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 45 | 51 | 96 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 25 | 48 |
| White | 327 | 320 | 647 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| Canada | 5 | 8 | 13 |
| Argentina | 92 | 84 | 176 |
| Romania | 35 | 41 | 76 |
| United States | 87 | 85 | 172 |
| Italy | 7 | 9 | 16 |
| Mexico | 100 | 104 | 204 |
| United Kingdom | 14 | 10 | 24 |
| Israel | 20 | 15 | 35 |
| Slovakia | 22 | 22 | 44 |
| Germany | 16 | 18 | 34 |
| Hemoglobin A1(Percentage of HbA1c) | Tirzepatide | Intensified Conventional Care (ICC) | Total |
|---|---|---|---|
| Mean | 7.83 ± 0.80 | 7.79 ± 0.84 | 7.81 ± 0.82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2022 to primary completion in Oct 2025, 38 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 38 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide